Franciose to lead Siemens nuclear group
Siemens Medical Systems has appointed Barbara Franciose as groupvice president of its nuclear medicine group in Hoffman Estates,IL. Franciose replaces Thomas Cafarella, who led the divisionfor two years (SCAN 7/14/93). Franciose is a Siemens veteran
Siemens Medical Systems has appointed Barbara Franciose as groupvice president of its nuclear medicine group in Hoffman Estates,IL. Franciose replaces Thomas Cafarella, who led the divisionfor two years (SCAN 7/14/93).
Franciose is a Siemens veteran who previously headed the vendor'sangiography division, which is also located at the nuclear group'sHoffman Estates facility. She has an engineering background, withdegrees from the University of Illinois and Marquette University.
Franciose's appointment comes amid other recent personnel changesat Siemens' nuclear medicine group, including the appointmentof Randy Weatherhead as vice president of sales and marketing(SCAN 9/27/95).
Siemens has been trying to rebuild its once-dominant positionin the nuclear medicine industry, but has found the going toughdue to the slumping gamma camera market and stiff competitionfrom other vendors.
In other Siemens personnel moves, Wolfgang Kroll has been namedexecutive vice president of business administration and financeat the vendor's Iselin, NJ, headquarters. Paul Mathews was namedgroup vice president of the firm's electromedical group.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
